Palatin Technologies Announces FDA Orphan Designation For PL7737 - Quick Facts

(RTTNews) - Palatin Technologies (PTN) announced the FDA has granted orphan drug designation to PL7737, an oral treatment that activates the melanocortin-4 receptor, for leptin receptor deficiency, including obesity caused by this condition.

Carl Spana, President and CEO of Palatin, said: "Currently, the only FDA-approved treatment for obesity due to leptin receptor deficiency is a daily injection. PL7737's oral form could provide a more convenient and effective option for these patients and others with rare genetic obesity disorders. We are also exploring PL7737 for hypothalamic obesity and plan to begin a Phase 1 SAD/MAD study in late 2025."

Shares of Palatin Technologies are up 8% in pre-market trade on Tuesday.

For More Such Health News, visit rttnews.com.